Mechanisms of disease relapse in acute lymphoblastic leukaemia

Mechanisms of disease relapse in acute lymphoblastic leukaemia

Project details

Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. While current treatments for ALL are effective at treating primary disease, relapse is common (~25%) and secondary treatment options are limited and ineffective. Development of new therapeutics and clinical biomarkers to determine the risk of disease relapse is required. This project will involve comprehensively profiling the proteins of primary and relapse ALL cells to identify specific mechanisms and pathways that contribute to disease relapse.

The aim of this project will be to use molecular biology, proteomic and biostatistical techniques to determine the mechanisms that cause ALL relapse. Additionally, this approach will identify novel diagnostic biomarkers that can better stratify disease beyond genetic markers in the hope of improving treatment efficacy.


About our research group

We have a specific interest in utilising advanced proteomic techniques to answer biological questions and develop treatments for disease. We have a strong record in both proteomics and leukaemia research (e.g. Hawkins, et. al., Nature 2016; Sandow, et. al., Prot. Clin. App. 2017; Witter, Sandow, et. al., Blood Adv. 2017, in press). This project will utilise these two strengths to identify why patients relapse following treatment and how we can personalize treatments to suit a patient’s particular circumstances.


Dr Andrew Webb

Dr Andrew Webb in the lab
Acting Division Head
Dr Jarrod Sandow profile shot
Systems Biology and Personalised Medicine division

Project Type: